Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir

Intern Med. 2021 Jul 1;60(13):2061-2066. doi: 10.2169/internalmedicine.6728-20. Epub 2021 Feb 1.

Abstract

A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.

Keywords: DAA; HCV genotype 4; Japan; cirrhosis; transfusion.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Benzimidazoles
  • Drug Combinations
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus* / genetics
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Japan
  • Liver Cirrhosis / drug therapy
  • Male
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Drug Combinations
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides
  • glecaprevir and pibrentasvir